Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DG49 | ISIN: US4834971032 | Ticker-Symbol: 4XC1
Tradegate
27.06.25 | 08:27
10,100 Euro
+2,54 % +0,250
1-Jahres-Chart
KALVISTA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
KALVISTA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,80010,00016:39
9,8509,95016:39

Aktuelle News zur KALVISTA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoKalVista Enters Into Licensing Agreement With Pendopharm To Commercialize Sebetralstat In Canada2
DoKalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada192-Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada- -Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic...
► Artikel lesen
DiKalvista stock volatile after report of FDA commissioner intervention1
DiFDA's Makary sought to reject KalVista's drug: report4
KALVISTA PHARMACEUTICALS Aktie jetzt für 0€ handeln
20.06.How KalVista Pharma Is Taking On A Rare But Deadly Disease1
16.06.FDA to miss approval deadline for Kalvista drug due to 'resource constraints'1
16.06.FDA delays Kalvista's sebetralstat decision due to resource constraints4
16.06.FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision7
16.06.KalVista's oral HAE treatment shows efficacy for breakthrough attacks2
16.06.FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision3
16.06.Kalvista stock steady as JMP reiterates $19 target amid FDA delay2
14.06.FDA Delays Decision On KalVista's Sebetralstat NDA For Hereditary Angioedema1
14.06.DRI Healthcare Trust Comments on FDA Delay for KalVista Pharmaceuticals' Sebetralstat PDUFA Goal Date Due to FDA Resourcing Constraints2
14.06.DRI Healthcare Trust: DRI notes FDA delay for KalVista's sebetralstat2
13.06.US FDA extends review of KalVista's swelling disorder drug due to heavy workload2
13.06.KalVista said FDA will not meet review date for sebetralstat1
13.06.FDA delays decision on KalVista's HAE treatment sebetralstat2
13.06.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints416FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks KalVista Pharmaceuticals, Inc. (Nasdaq: KALV)...
► Artikel lesen
05.06.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025270KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place...
► Artikel lesen
02.06.KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management245-Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials- -Sebetralstat data demonstrated rapid relief and resolution of severe...
► Artikel lesen
Weiter >>
84 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1